Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non-Current Liabilities (2017 - 2025)

Northwest Biotherapeutics' Other Non-Current Liabilities history spans 15 years, with the latest figure at $47.1 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $47.1 million for Q4 2025, up 1.95% from a year ago — trailing twelve months through Dec 2025 was $47.1 million (up 1.95% YoY), and the annual figure for FY2025 was $47.1 million, up 1.95%.
  • Other Non-Current Liabilities for Q4 2025 was $47.1 million at Northwest Biotherapeutics, down from $60.8 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $350.4 million in Q1 2021 to a low of $10.0 million in Q2 2023.
  • The 5-year median for Other Non-Current Liabilities is $47.7 million (2025), against an average of $92.6 million.
  • The sharpest move saw Other Non-Current Liabilities soared 1764.24% in 2021, then plummeted 90.29% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $116.0 million in 2021, then fell by 21.8% to $90.7 million in 2022, then tumbled by 74.22% to $23.4 million in 2023, then soared by 97.4% to $46.2 million in 2024, then increased by 1.95% to $47.1 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $47.1 million, $60.8 million, and $48.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.